Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Covington
Moodys
McKesson
Deloitte
US Department of Justice
US Army
Merck
Citi

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RADIUM RA-223 DICHLORIDE

« Back to Dashboard

Clinical Trials for Radium Ra-223 Dichloride

Trial ID Title Status Sponsor Phase Summary
NCT00699751 A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases Completed Bayer Phase 3 ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases.
NCT01516762 Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases No longer available Bayer N/A This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term safety data on the product.
NCT01618370 Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases Completed Bayer Phase 3 This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product.
NCT01810770 Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis Active, not recruiting Bayer Phase 3 To evaluate the safety and efficacy (Overall survival [OS]) of multiple doses of Ra-223 dichloride in an Asian population of subjects with CRPC metastatic to the bone.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Radium Ra-223 Dichloride

Condition Name

Condition Name for Radium Ra-223 Dichloride
Intervention Trials
Prostatic Neoplasms 7
Bone Metastases 4
Prostate Cancer 3
Prostate Carcinoma Metastatic to the Bone 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Radium Ra-223 Dichloride
Intervention Trials
Prostatic Neoplasms 19
Neoplasm Metastasis 8
Bone Neoplasms 3
Bone Marrow Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Radium Ra-223 Dichloride

Trials by Country

Trials by Country for Radium Ra-223 Dichloride
Location Trials
United States 186
United Kingdom 53
Italy 50
Germany 46
Spain 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Radium Ra-223 Dichloride
Location Trials
New York 11
California 11
Maryland 9
Pennsylvania 9
Washington 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Radium Ra-223 Dichloride

Clinical Trial Phase

Clinical Trial Phase for Radium Ra-223 Dichloride
Clinical Trial Phase Trials
Phase 3 4
Phase 2 12
Phase 1/Phase 2 6
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Radium Ra-223 Dichloride
Clinical Trial Phase Trials
Active, not recruiting 8
Not yet recruiting 6
Recruiting 6
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Radium Ra-223 Dichloride

Sponsor Name

Sponsor Name for Radium Ra-223 Dichloride
Sponsor Trials
Bayer 15
National Cancer Institute (NCI) 2
Carolina Research Professionals, LLC 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Radium Ra-223 Dichloride
Sponsor Trials
Industry 20
Other 13
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Accenture
Healthtrust
McKinsey
US Department of Justice
Farmers Insurance
Express Scripts
Cantor Fitzgerald
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.